Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
New research from the Icahn School of Medicine at Mount Sinai shows that microRNA-128 is one of the strongest regulators of nerve cell excitability and motor activity, and that it does so by adjusting an entire neuronal signaling pathway. Published online in the journal Science, the preclinical study suggests that developing new drugs for treatment-refractory epilepsy that target the microRNA signaling pathway might prove beneficial for patients with severe epilepsy, including the epilepsy of infancy. MicroRNAs are non-coding RNAs that regulate the translation or degradation of messenger RNA, the essential building blocks for proteins in the cell.
Anne Schaefer, MD, PhD, Assistant Professor, Seaver Fellow, and recipient of the NIH Director's New Innovator Award 2012 Friedman Brain Institute, Departments of Neuroscience and Psychiatry, at the Icahn School of Medicine at Mount Sinai, and the study's senior author, said that the findings are extremely compelling. "This is the first time that it has been shown that a single microRNA could control complex functions in the adult brain." The investigators revealed that the expression of a single microRNA, microRNA-128, defined motor activity and exploration in mice. When miR-128 expression was reduced in adult neurons, it led to a dose-dependent increase in motor activity and fatal epilepsy. Over-expression of the miRNA lessens neuronal responsiveness and seizure susceptibility, reduces motor activity, and reduces motor difficulties associated with Parkinson's like disease.
Mount Sinai Innovation Partners is managing the intellectual property for the use of microRNA-128 as a potential treatment for severe and treatment-refractory epilepsy and exploring commercial opportunities for this technology.
Other contributors to this research are Melanie von Schimmelmann, Philip Feinberg, and Anne Schaefer from the Icahn School of Medicine at Mount Sinai, Chan Lek Tan, PhD, who is the lead author of the study, Silas Mann, PhD, Annie Handler, PhD, and Paul Greengard, PhD, from The Rockefeller University in New York, Joshua L. Plotkin and D. James Surmeier from the Northwestern University's Feinberg School of Medicine in Chicago, Morten T. Venø and Jørgen Kjems from the Aarhus University in Denmark, and Donal O'Carroll from the European Molecular Biology Laboratory in Italy.
This research was supported by the National Institutes of Health, the Seaver Autism Foundation, the Department of Defense, the Lundbeck Foundation and Center for Integrative Sequencing at Aarhus University, the Jeffry M. & Barbara Picower Foundation, and the CHDI Foundation.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Epilepsy category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
The Mount Sinai Hospital / Mount Sinai School of M. "Finding that single microRNA powers motor activity has implications for treating severe treatment-refractory epilepsy." Medical News Today. MediLexicon, Intl., 9 Dec. 2013. Web.
9 Mar. 2014. <http://www.medicalnewstoday.com/releases/269817>
The Mount Sinai Hospital / Mount Sinai School of M. (2013, December 9). "Finding that single microRNA powers motor activity has implications for treating severe treatment-refractory epilepsy." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/269817.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.